Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $861031.0.

  • Iradimed's Change in Accured Expenses rose 12686.95% to $861031.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $786950.0, marking a year-over-year decrease of 4130.84%. This contributed to the annual value of $996653.0 for FY2024, which is 29866.12% up from last year.
  • According to the latest figures from Q3 2025, Iradimed's Change in Accured Expenses is $861031.0, which was up 12686.95% from $943503.0 recorded in Q2 2025.
  • In the past 5 years, Iradimed's Change in Accured Expenses registered a high of $943503.0 during Q2 2025, and its lowest value of -$1.5 million during Q1 2025.
  • Its 5-year average for Change in Accured Expenses is $131548.2, with a median of $391692.0 in 2022.
  • In the last 5 years, Iradimed's Change in Accured Expenses skyrocketed by 100851.57% in 2021 and then tumbled by 15266.67% in 2023.
  • Over the past 5 years, Iradimed's Change in Accured Expenses (Quarter) stood at $400574.0 in 2021, then dropped by 20.53% to $318353.0 in 2022, then soared by 161.25% to $831699.0 in 2023, then crashed by 41.38% to $487530.0 in 2024, then skyrocketed by 76.61% to $861031.0 in 2025.
  • Its Change in Accured Expenses stands at $861031.0 for Q3 2025, versus $943503.0 for Q2 2025 and -$1.5 million for Q1 2025.